George Tidmarsh is a millionaire co-founder of a biotech firm, serial entrepreneur, neonatologist and adjunct professor at Stanford University. But his part in creating a fringe medical journal is the role that stands out as he takes a top post at the US Food and Drug Administration.

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments.

“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — from bench to bedside,” FDA Commissioner Marty Makary said in a statement. “His appointment to lead CDER brings exceptional scientific, regulatory, and operational expertise to the agency.”

Ticker: Americans putting money in investment income; FDA names former pharmaceutical company executive to oversee US drug program

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising medications, the Congressional Budget Office said on Friday.

US Food and Drug Administration Commissioner Marty Makary signaled Thursday that he is open to revising strict warning labels on Hormone Replacement Therapy.

Secretary Kennedy says the latest announcement demonstrates how the administration is holding the food industry accountable.

WASHINGTON (AP) — The Food and Drug Administration is allowing vaping brand Juul to keep its e-cigarettes on the market. Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.